Jennifer L Clarke

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Leptomeningeal metastasis from systemic cancer
    Jennifer L Clarke
    University of California, San Francisco, 400 Parnassus Avenue, A 808, Box 0372, San Francisco, CA 94143, USA
    Continuum (Minneap Minn) 18:328-42. 2012
  2. ncbi Neuroimaging: diagnosis and response assessment in glioblastoma
    Jennifer L Clarke
    Department of Neurological Surgery, Division of Neuro Oncology, University of California San Francisco, San Francisco, CA 94143 0372, USA
    Cancer J 18:26-31. 2012
  3. ncbi Pseudoprogression and pseudoresponse: challenges in brain tumor imaging
    Jennifer L Clarke
    Department of Neurological Surgery, Division of Neuro Oncology, University of California San Francisco, 400 Parnassus Avenue, A 808, Box 0372, San Francisco, CA 94143, USA
    Curr Neurol Neurosci Rep 9:241-6. 2009
  4. ncbi Recent advances in therapy for glioblastoma
    Jennifer Clarke
    Division of Neuro Oncology, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Ave, Room A 808, Box 0372, San Francisco, CA 94143 0372, USA
    Arch Neurol 67:279-83. 2010
  5. ncbi Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
    Jennifer L Clarke
    Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A 808, San Francisco, CA 94143 0372, USA
    Neuro Oncol 13:1118-24. 2011
  6. ncbi Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment
    Aaron J Clark
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, California 94143 0112, USA
    Neurosurgery 70:361-70. 2012
  7. ncbi Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide
    Mei Yin C Polley
    Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, Room A 808, Box 0372, San Francisco, California 94143 2167, USA
    Neuro Oncol 12:274-82. 2010
  8. ncbi Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy
    Patrick G Morris
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 7:382-5. 2012

Detail Information

Publications8

  1. ncbi Leptomeningeal metastasis from systemic cancer
    Jennifer L Clarke
    University of California, San Francisco, 400 Parnassus Avenue, A 808, Box 0372, San Francisco, CA 94143, USA
    Continuum (Minneap Minn) 18:328-42. 2012
    ..Leptomeningeal metastasis (LM) is an uncommon, usually late, complication of cancer. This article discusses the clinical presentation, diagnosis, prognosis, and treatment of LM...
  2. ncbi Neuroimaging: diagnosis and response assessment in glioblastoma
    Jennifer L Clarke
    Department of Neurological Surgery, Division of Neuro Oncology, University of California San Francisco, San Francisco, CA 94143 0372, USA
    Cancer J 18:26-31. 2012
    ....
  3. ncbi Pseudoprogression and pseudoresponse: challenges in brain tumor imaging
    Jennifer L Clarke
    Department of Neurological Surgery, Division of Neuro Oncology, University of California San Francisco, 400 Parnassus Avenue, A 808, Box 0372, San Francisco, CA 94143, USA
    Curr Neurol Neurosci Rep 9:241-6. 2009
    ..This article reviews the challenges of brain tumor imaging and its use in assessment of treatment response...
  4. ncbi Recent advances in therapy for glioblastoma
    Jennifer Clarke
    Division of Neuro Oncology, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Ave, Room A 808, Box 0372, San Francisco, CA 94143 0372, USA
    Arch Neurol 67:279-83. 2010
    ....
  5. ncbi Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
    Jennifer L Clarke
    Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A 808, San Francisco, CA 94143 0372, USA
    Neuro Oncol 13:1118-24. 2011
    ....
  6. ncbi Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment
    Aaron J Clark
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, California 94143 0112, USA
    Neurosurgery 70:361-70. 2012
    ..The management and prognosis of glioblastoma patients after Stupp protocol treatment and progression during bevacizumab (BV) treatment remain undefined...
  7. ncbi Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide
    Mei Yin C Polley
    Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, Room A 808, Box 0372, San Francisco, California 94143 2167, USA
    Neuro Oncol 12:274-82. 2010
    ..Our analysis suggests that 6-month PFS may be an appropriate primary endpoint in the context of phase II upfront GBM trials in the TMZ era...
  8. ncbi Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy
    Patrick G Morris
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 7:382-5. 2012
    ..A retrospective review was carried out to assess the impact of whole brain radiotherapy (WBRT), intrathecal therapy (IT), and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) on outcomes...